Clinical Trials Browser

Phase 3 × Has results × Vorinostat × Clear all

Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00773747 2021-04-30

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT00128102 2020-10-26

MK-0683-014

Phase 3 Completed

661 enrolled 18 charts

Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

NCT01802333 2018-12-19

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Phase 3 Completed

754 enrolled 20 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

MK-0683-014

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia